Retroviral and lentiviral vectors expressing inhibitor-resistant MGMT mutants have been utilized to protect against the myelosuppressive toxicity of chemotherapy drugs and prevent therapy-related secondary hematopoietic malignancies [195,196,197,198,199,200]. The gene discussed is MGMT; the disease is cancer.